At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of acute myeloid leukemia, myelodysplasia, or biphenotypic leukemia confirmed by immunophenotyping, morphology, and/or cytochemical staining
- ✓Age ≤21 years at study entry
- ✓No prior therapy for this malignancy except one dose of intrathecal therapy (patients with secondary AML following treatment of primary malignancy are eligible)
- ✓Negative pregnancy test
- ✕Positive pregnancy test
- ✕Down syndrome
- ✕Acute promyelocytic leukemia (APL)
- ✕Juvenile myelomonocytic leukemia (JMML)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
In Brief
A Phase 3 clinical trial evaluating Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone and Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine for Leukemia, Myelocytic, Acute. Completed, enrolled 238 participants across 8 sites.
Detailed Summary
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Study Details
Timeline
Interventions
Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs